Quanterix Q1 Revenues Fall 4 Percent as Instrument Sales Decline
Product and service and other revenues were both down year over year, while collaboration and grant revenues rose.
Oncocyte Prices $13.9M Stock Offering, Reports 69 Percent Drop in Preliminary Q4 Revenues
The Irvine, California-based molecular diagnostics firm reported $1.1 million in Q4 2022 revenues and $5.6 million in full-year 2022 revenues.
Castle Biosciences Estimates 2022 Revenues in Line With Prior Projections
The company said it expects full-year revenues of at least $132 million to $137 million, with test volumes up significantly across the majority of its menu.
Exact Sciences Projects 28 Percent Bump in Total Q4 Oncology Revenue
The company expects to report consistent growth in both cancer screening and precision oncology testing for the quarter and the full fiscal year.
Sema4 Changes Name to GeneDx, Provides Preliminary 2022 Revenues, 2023 Guidance
As it exits reproductive health screening this quarter, the newly renamed GeneDx expects 2022 revenues of $170 million to $173 million and 2023 revenues of $205 million to $220 million in pursuit of profitability by 2025.